Jean-Louis Excler1, Nelson L Michael. 1. aUS Military HIV Research Program, Henry M. Jackson Foundation, Bethesda, Maryland, USAbInternational Vaccine Institute, SNU Research Park, Seoul, Republic of KoreacUS Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Abstract
PURPOSE OF REVIEW: Only four HIV-1 vaccine concepts have been tested in six efficacy trials with no product licensed to date. Several scientific and programmatic lessons can be learned from these studies generating new hypotheses and guiding future steps. RECENT FINDINGS: RV144 [ALVAC-HIV (canarypox vector) and AIDSVAX B/E (bivalent gp120 HIV-1 subtype B and CRF01_AE)] remains the only efficacy trial that demonstrated a modest vaccine efficacy, which led to the identification of immune correlates of risk. Progress on subtype-specific, ALVAC (canarypox vector) and gp120 vaccine prime-boost approaches has been slow, but we are finally close to the launch of an efficacy study in Africa in 2016. The quest of a globally effective HIV-1 vaccine has led to the development of new approaches. Efficacy studies of combinations of Adenovirus type 26 (Ad26)/Modified Vaccinia Ankara (MVA)/gp140 vaccines with mosaic designs will enter efficacy studies mid-2017 and cytomegalovirus (CMV)-vectored vaccines begin Phase I studies at the same time. Future HIV-1 vaccine efficacy trials face practical challenges as effective nonvaccine prevention programs are projected to decrease HIV-1 incidence. SUMMARY: An HIV-1 vaccine is urgently needed. Increased industry involvement, mobilization of resources, expansion of a robust pipeline of new concepts, and robust preclinical challenge studies will be essential to accelerate efficacy testing of next generation HIV-1 vaccine candidates.
PURPOSE OF REVIEW: Only four HIV-1 vaccine concepts have been tested in six efficacy trials with no product licensed to date. Several scientific and programmatic lessons can be learned from these studies generating new hypotheses and guiding future steps. RECENT FINDINGS: RV144 [ALVAC-HIV (canarypox vector) and AIDSVAX B/E (bivalent gp120HIV-1 subtype B and CRF01_AE)] remains the only efficacy trial that demonstrated a modest vaccine efficacy, which led to the identification of immune correlates of risk. Progress on subtype-specific, ALVAC (canarypox vector) and gp120 vaccine prime-boost approaches has been slow, but we are finally close to the launch of an efficacy study in Africa in 2016. The quest of a globally effective HIV-1 vaccine has led to the development of new approaches. Efficacy studies of combinations of Adenovirus type 26 (Ad26)/Modified Vaccinia Ankara (MVA)/gp140 vaccines with mosaic designs will enter efficacy studies mid-2017 and cytomegalovirus (CMV)-vectored vaccines begin Phase I studies at the same time. Future HIV-1 vaccine efficacy trials face practical challenges as effective nonvaccine prevention programs are projected to decrease HIV-1 incidence. SUMMARY: An HIV-1 vaccine is urgently needed. Increased industry involvement, mobilization of resources, expansion of a robust pipeline of new concepts, and robust preclinical challenge studies will be essential to accelerate efficacy testing of next generation HIV-1 vaccine candidates.
Authors: Diane G Carnathan; Joseph J Mackel; Shelby L Sweat; Chiamaka A Enemuo; Etse H Gebru; Pallavi Dhadvai; Sailaja Gangadhara; Sakeenah Hicks; Thomas H Vanderford; Rama R Amara; José Esparza; Wei Lu; Jean-Marie Andrieu; Guido Silvestri Journal: J Virol Date: 2018-04-27 Impact factor: 5.103
Authors: Peng Zhang; Elisabeth Narayanan; Qingbo Liu; Yaroslav Tsybovsky; Kristin Boswell; Shilei Ding; Zonghui Hu; Dean Follmann; Yin Lin; Huiyi Miao; Hana Schmeisser; Denise Rogers; Samantha Falcone; Sayda M Elbashir; Vladimir Presnyak; Kapil Bahl; Madhu Prabhakaran; Xuejun Chen; Edward K Sarfo; David R Ambrozak; Rajeev Gautam; Malcom A Martin; Joanna Swerczek; Richard Herbert; Deborah Weiss; Johnathan Misamore; Giuseppe Ciaramella; Sunny Himansu; Guillaume Stewart-Jones; Adrian McDermott; Richard A Koup; John R Mascola; Andrés Finzi; Andrea Carfi; Anthony S Fauci; Paolo Lusso Journal: Nat Med Date: 2021-12-09 Impact factor: 53.440
Authors: Peng Zhang; Jason Gorman; Hui Geng; Qingbo Liu; Yin Lin; Yaroslav Tsybovsky; Eden P Go; Barna Dey; Tsion Andine; Alice Kwon; Mit Patel; Deepali Gururani; Ferzan Uddin; Christina Guzzo; Raffaello Cimbro; Huiyi Miao; Krisha McKee; Gwo-Yu Chuang; Loïc Martin; Francesca Sironi; Mauro S Malnati; Heather Desaire; Edward A Berger; John R Mascola; Michael A Dolan; Peter D Kwong; Paolo Lusso Journal: Cell Host Microbe Date: 2018-06-13 Impact factor: 21.023
Authors: Carmen Elena Gómez; Beatriz Perdiguero; Cristina Sánchez-Corzo; Carlos Oscar S Sorzano; Mariano Esteban Journal: Viruses Date: 2017-12-27 Impact factor: 5.048